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A b s t r a c t
Glycated hemoglobin is widely used in the 
management of diabetes mellitus. At least 300,000 
Americans with diabetes mellitus have the hemoglobin 
(Hb) C or S trait. The accuracy o f HbAlc methods can 
be adversely affected by the presence o f these traits. 
We evaluated the effects o f HbC and HbS traits on 
the results o f 14 commercial HbA1c methods that use 
boronate affinity, enzymatic, immunoassay, and ion 
exchange methods. Whole blood samples from people 
homozygous for HbA or heterozygous for HbC or HbS 
were analyzed for HbA1c. Results for each sample 
type were compared with those from the CLC 330 
comparative method (Primus Diagnostics, Kansas 
City, MO). After correcting for calibration bias by 
comparing results from the homozygous HbA group, 
method bias attributable to the presence o f HbC or 
HbS trait was evaluated with a clinically significant 
difference being more than 10% (ie, 0.6% at 6%  
HbA1c). One immunoassay method exhibited clinically 
significant differences owing to the presence o f HbC 
and HbS traits.
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Glycated hemoglobin, reported as HbA1c, is a bio­
chemical marker that is routinely used in the management 
of diabetes mellitus to monitor long-term glycemic control 
and assess the risk of developing complications.1-3 The 
presence of hemoglobin (Hb) C or S trait has been shown 
to affect the accuracy of some HbA1c assays.4-9 In 2004, 
there were 23.5 million non-Hispanic blacks aged 18 years 
or older in the United States,10 of whom at least 10% have 
HbC or HbS trait.11 The prevalence o f diabetes mellitus, 
diagnosed and undiagnosed, in non-Hispanic black men is 
13.0% and in non-Hispanic black women is 16.3%.12 This 
works out to between 305,000 and 383,000 people who 
have diabetes mellitus and HbC or HbS trait.
Because o f the number of patients with diabetes 
mellitus who could potentially be affected by inaccurate 
H bA1c results due to interference by the presence o f HbC 
or HbS trait, we continued our earlier investigations and 
evaluated the effects o f HbC and HbS traits on the results 
o f 14 commercial HbA1c methods that use ion exchange 
chromatography (6 methods), immunoassay (5 methods), 
boronate affinity (2 methods), and enzymatic (1 method) 
techniques. Nearly all o f the methods evaluated in this 
study have not been previously evaluated in a rigorous 
manner for interference from the presence o f HbC or 
HbS trait. This is the first time that we have evaluated 
an enzymatic assay for H bA1c for the possibility o f inter­
ference by Hb variants. We reexamined 2 ion exchange 
methods to see whether they currently have interference 
issues because we have previously shown there may be 
lot-to-lot variability in susceptibility to interference by 
Hb traits for some H bA  methods.8-91c
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Materials and Methods
Whole blood samples from people homozygous for HbA 
(n = 68) and heterozygous for HbC or HbS (n = 58 and n = 72, 
respectively) were collected in EDTA tubes. The clinical site 
for sample collection was located in an urban area with a high 
proportion of African American patients so there would be a 
good opportunity to identify samples with HbC or HbS traits. 
After routine clinical testing had been completed, Hb variants 
were identified by inspection of chromatograms obtained with 
a VARIANT analyzer (Bio-Rad Laboratories, Hercules, CA) 
using the Beta Thal Short Program run according to manu­
facturer’ s instructions. No additional confirmatory testing of 
samples containing Hb variants was performed. Aliquots of 
these samples that had HbA1c results between 4% and 14% 
(0.04-0.14) were analyzed within 7 days by using the Afinion 
AS100 method (Axis Shield, Norton, MA) and stored at 
-70°C for analysis by the other methods. Not all samples were 
analyzed by every method. Studies with samples from human 
subjects were approved by the University of Utah Institutional 
Review Board (Salt Lake City).
Samples were analyzed by the following assays and instru­
ments: Afinion AS100; ultra2, Primus Diagnostics, Kansas 
City, MO; Diazyme reagents, Diazyme Laboratories, Poway, 
CA, on a Modular P analyzer, Roche Diagnostics, Indianapolis, 
IN; COBAS INTEGRA 800 generation 2, Roche Diagnostics; 
Microgenics reagents, Microgenics, Fremont, CA, on a Modular 
P analyzer; Olympus AU400 HbA1c/THb (Olympus, Center 
Valley, PA); Pointe Scientific reagents, Pointe Scientific, 
Canton, MI, on an Olympus AU400 analyzer; VITROS 5,1 
FS, Ortho Clinical Diagnostics, Rochester, NY; D-10 Short 
Program (3 minutes), D-10 Extended Program (6 minutes), 
VARIANT, VARIANT II, and VARIANT II TURBO, Bio­
Rad Laboratories, Hercules, CA; and G7, Tosoh Biosciences, 
San Francisco, CA. All assays were performed according to 
the manufacturers’ instructions. The CLC 330 boronate affin­
ity method (Primus Diagnostics) was used as the compara­
tive method in a National Glycohemoglobin Standardization 
Program (NGSP) Network Laboratory with in-house calibrator 
materials. This method has previously been shown to be unaf­
fected by the presence of HbC and HbS traits.13 Results for all 
methods were reported as NGSP HbA1c equivalents.
For each method, results for each type of sample (homozy­
gous HbA, heterozygous HbC, and heterozygous HbS) were 
compared with results from the CLC330 method. An overall 
test of coincidence of 2 least-square linear regression lines was 
performed with SAS software (SAS Institute, Cary, NC) to 
determine whether the presence of HbC or HbS trait produced a 
statistically significant difference (P < .01) in results relative to 
the comparative method. To determine whether the presence of 
HbC or HbS trait produced clinically significant effects on the 
HbA1c results, we chose evaluation limits of 6% and 9% based
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on recommendations by the American Diabetes Association 
of an upper reference limit of 6% (0.06) and a general goal of 
7% (0.07) and the Diabetes Control and Complications Trial 
conventional treatment group mean HbA1c of approximately 
9% (0.09). Deming regression analysis was performed to 
estimate the average bias at 6% (0.06) and 9% (0.09) HbA1c. 
After correcting for possible calibration bias by comparing 
results from the homozygous HbA sample group, evaluation 
of method bias attributable to the presence of HbC or HbS trait 
was performed. A relative deviation of greater than 10% (ie, 
0.6% at 6% HbA1c and 0.9% at 9% HbA1c) compared with the 
homozygous HbA sample group was used to define a clinically 
significant difference. This 10% relative difference has been 
used in previous studies.7-9,14
Results
Information on the number of samples analyzed by each 
method for each sample type and the average biases at 6% 
(0.06) and 9% (0.09) HbA1c due to the presence of HbC and 
HbS traits are shown ITable 1 . We observed no clinically 
significant differences attributable to the presence of HbC 
or HbS trait for any assay except the Olympus AU400. The 
Olympus HbA1c method demonstrated a clinically significant 
positive bias for HbC and HbS trait samples at both evaluation 
limits of 6% (0.06) and 9% (0.09). The package insert for this 
method indicates that samples containing HbC or HbS trait 
can have result elevations of 40% due to the presence o f these 
variants. An abstract indicated that samples containing HbC 
and HbS traits showed maximum positive biases of 43% and 
32%, respectively, when analyzed by the Olympus method 
compared with the VARIANT II method.15 This information 
is consistent with our data.
Box plots for each combination of sample type and assay 
are shown IFigure 1 . The presence of HbC trait produced 
statistically significant differences (P < .01) for all meth­
ods except the Afinion AS100, D-10 Extended, ultra2, and 
VARIANT II TURBO methods. The presence of HbS trait 
produced statistically significant differences only for the G7, 
Microgenics, Olympus, Pointe Scientific, and VARIANT 
II methods. One other interesting observation is that the 
G7, Microgenics, and Pointe Scientific methods showed an 
increased range of differences with the comparative method 
for samples containing HbS trait compared with the differ­
ences seen for samples homozygous for HbA and those con­
taining HbC trait.
Discussion
Some previous studies have shown clinically significant 
effects on HbA1c measurements by the presence of HbC or 
HbS trait with certain ion exchange methods, unlike the
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Table 1!
Mean Differences Between Test and Comparative Methods for Samples Containing the HbC or HbS Trait*
Assay Principle/Method
HbC Trait HbS Trait
No. of Samples 6% (0.06) HbA1c 9% (0.09) HbA1c No. of Samples 6% (0.06) HbA1c 9% (0.09) HbA1c
>oronate affinity
Afinion AS100 40 -0.06 -0.12 39 -0.10 -0.11
ultra2 58 0.00 -0.09 71 0.03 -0.09
Enzymatic
Diazyme 27 -0.19 -0.53 28 -0.14 -0.24
Immunoassay
CO>AS INTEGRA 800 27 -0.28 -0.55 28 -0.08 -0.21
generation 2
Microgenics 28 0.30 0.07 42 0.08 -0.37
Olympus AU400 27 2.28+ 3.57 + 28 1.36 + 2.25 +
Pointe Scientific 31 0.59 0.20 43 0.32 -0.16
VITROS 5,1 FS 31 -0.28 -0.24 43 -0.25 0.15
Ion exchange
D-10 short 27 -0.10 -0.24 28 -0.02 -0.38
D-10 extended 27 0.09 -0.29 28 -0.08 -0.41
VARIANT 30 -0.45 -0.38 42 0.08 -0.24
VARIANT II 31 0.21 0.29 41 0.52 0.47
VARIANT II TUR>O 31 0.17 0.14 43 0.04 -0.13
G7 31 -0.38 -0.29 43 -0.36 -0.82
Hb, hemoglobin.
* Deming regression analysis was performed using the CLC 330 (Primus Diagnostics, Kansas City, MO) as the comparative method. The average differences (%) of each of the
other methods at clinical decision cutoffs of 6% and 9% were calculated for each Hb trait. To correct for intermethod calibration differences, the mean difference between the 
method of interest and the comparative method for homozygous HbA samples was subtracted from that calculated for samples containing the HbC or HbS trait. Afinion AS 100, 
Axis Shield, Norton, MA; ultra2, Primus Diagnostics, Kansas City, MO; COBAS INTEGRA 800 generation 2, Roche Diagnostics, Indianapolis, IN; Microgenics, Microgenics, 
Fremont, CA; Olympus AU400, Olympus, Center Valley, PA; Pointe Scientific, Pointe Scientific, Canton, MI; VITROS 5,1 FS, Ortho Clinical Diagnostics, Rochester, NY; 
D-10 Short Program (3 min), D-10 Extended Program (6 min), VARIANT, VARIANT II, and VARIANT II TURBO, Bio-Rad Laboratories, Hercules, CA; and G7, Tosoh 
Biosciences, San Francisco, CA.
* Clinically significant differences (>0.6% or >0.9% HbA^  at 6% or 9% HbA^ , respectively) were found.
Afinion ultra3 Diazyme COBAS Microgenics Olympus Pointe VITROS D-10 D-10 VARIANT VARIANT II VARIANT II GT 
AS100 INTEGRA 800 AU400 Scientific 5,1 FS Short Extended TURBO
Figure 1 >ox plots summarizing the absolute differences between each assay and the comparative method for each 
hemoglobin phenotype. The horizontal line inside each box is the median difference between the test and comparative 
methods. The upper and lower limits of each box correspond to the 25th and 75th percentiles of the differences, respectively. 
The upper and lower bars represent the maximum and minimum differences between the test and comparative methods. 
Differences from those obtained for homozygous hemoglobin A results that are statistically significant (P < .01) are indicated (*), 
as are clinically significant differences (+). Afinion AS100, Axis Shield, Norton, MA; ultra2, Primus Diagnostics, Kansas City, MO; 
CO>AS INTEGRA 800 generation 2, Roche Diagnostics, Indianapolis, IN; Microgenics, Microgenics, Fremont, CA; Olympus 
AU400, Olympus, Center Valley, PA; Pointe Scientific, Pointe Scientific, Canton, MI; VITROS 5,1 FS, Ortho Clinical Diagnostics, 
Rochester, NY; D-10 Short Program (3 min), D-10 Extended Program (6 min), VARIANT, VARIANT II, and VARIANT II TUR>O, 
>io-Rad Laboratories, Hercules, CA; and G7, Tosoh >iosciences, San Francisco, CA.
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present study in which all of these methods showed clini­
cally nonsignificant effects. The G7 ion exchange method 
showed statistically but not clinically significant negative 
biases for samples with HbC and HbS traits, which is in 
agreement with the findings of a previous study.14 However, 
in the present study, the net negative bias for the G7 method 
with samples containing the HbS trait estimated from 
Deming regression analysis at the 9% (0.09) HbA1c evalu­
ation limit was close to the limit of -0.9%. The VARIANT 
ion exchange method for HbA1c has been previously report­
ed to exhibit positive bias with samples containing the HbS 
trait.8,9 In the present study, it exhibited a slight positive 
bias at the 6% (0.06) evaluation limit that was not clinically 
significant. The VARIANT II method has been previously 
shown to exhibit positive clinically significant biases for 
samples containing both HbC and HbS traits, but our results 
in the present study show a net positive bias with VARIANT 
II that is not clinically significant.9,14 We have not yet 
evaluated the newly released VARIANT II NU reagents. 
Differences between the results obtained in this study and 
previous studies are consistent with lot-to-lot variability or 
intentional improvements in the response of ion exchange 
methods to interference by Hb variants.
Of the 5 immunoassays evaluated in the present study, 
the COBAS INTEGRA 800 method exhibited negative net 
biases estimated from Deming regression analysis for HbC 
and HbS traits at both evaluation limits, whereas the Olympus 
method exhibited positive net biases for both traits at both 
limits. The previous reagents used on the COBAS INTEGRA 
800 had shown a clinically significant positive bias with 
samples containing the HbC or HbS trait.4,7,8 The data from 
the current generation 2 assay on the COBAS INTEGRA 
800 agree with another recent study indicating no clinically 
significant bias for either trait.16
For all immunoassay methods examined in this study, 
only 1, the Olympus method, demonstrated clinically sig­
nificant effects from HbC and HbS traits. For both HbC and 
HbS traits, HbA was overestimated, which could lead to1c
overly rigorous glycemic control with consequent hypogly­
cemia. Attention to the effects of Hb variants on the results 
of HbA1c methods is necessary to ensure accurate results 
for people who have an Hb variant and diabetes mellitus. 
Furthermore, for methods that do not allow the operator to 
identify the presence of an Hb variant, including boronate 
affinity, enzymatic, and immunoassay, if the method is 
affected to a clinically significant extent by a particular Hb 
variant that will be encountered in the patient population 
being tested, it may be necessary to determine the Hb pheno­
type of each patient with diabetes mellitus. If a patient with an 
Hb variant that interferes with the routine HbA1c method is 
identified, all samples from that patient will need to be tested 
by an alternative method that is not prone to interference by
the particular Hb variant. Alternatively, instead of determin­
ing the Hb phenotype of each patient, a comment could be 
added to each HbA1c result indicating that the possibility of 
an Hb variant interference should be considered if the H bA1c
result is not consistent with the mean plasma glucose level 
estimated by the patient’ s self-monitoring results or clinical 
estimates of glycemic control.
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